Suggestions for thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19

Casini Alessandro\textsuperscript{a}, Alberio Lorenzo\textsuperscript{b}, Angelillo-Scherrer Anne\textsuperscript{c}, Fontana Pierre\textsuperscript{d}, Gerber Bernhard\textsuperscript{d}, Graf Lukas\textsuperscript{a}, Hegemann Inga\textsuperscript{a}, Korte Wolfgang\textsuperscript{a}, Kremer Hovinga Johanna A.\textsuperscript{e}, Lecompte Thomas\textsuperscript{f}, Martinez Maria\textsuperscript{g}, Nagler Michael\textsuperscript{f}, Studt Jan-Dirk\textsuperscript{h}, Tsakiris Dimitrios\textsuperscript{i}, Wuillemin Walter\textsuperscript{a}, Asmis Lars M.\textsuperscript{j}, Working Party on Hemostasis of the Swiss Society of Hematology

\textsuperscript{a} Division of Angiology and Haemostasis, University Hospitals of Geneva, Geneva, Switzerland
\textsuperscript{b} Service and Central Laboratory of Hematology, Lausanne University Hospital, Lausanne, Switzerland
\textsuperscript{c} Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
\textsuperscript{d} Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
\textsuperscript{e} Cantonal Hospital of St Gallen, St Gallen, Switzerland
\textsuperscript{f} Department of Medical Oncology and Hematology, Zurich University Hospital, Zurich, Switzerland
\textsuperscript{g} Division of Hematology, University Hospitals of Geneva, Geneva, Switzerland
\textsuperscript{h} Division of Hematology, Basel University Hospital, Basel, Switzerland
\textsuperscript{i} Division of Hematology and Central Hematology Laboratory, Cantonal Hospital of Lucerne, Lucerne, Switzerland
\textsuperscript{j} Center for perioperative Thrombosis and Hemostasis, Zurich, Switzerland

Growing evidence from multiple retrospective cohorts indicates that hospitalised COVID-19 patients often could suffer from an excessive coagulation activation leading to an increased risk of venous and arterial thrombosis (including small calibre vessels) and a poor clinical course \cite{1}. Notably, D-dimer level at the time of hospital admission is a predictor of the risk of development of acute respiratory distress syndrome (ARDS) \cite{2}, the risk of intensive care admission and the risk of death \cite{3}. An observational study among COVID-19 patients with elevated D-dimer levels at baseline showed that the 28-day mortality was lower in those receiving heparin than in those who did not \cite{4}.

Based on the available literature and published recommendations from the International Society of Thrombosis and Hemostasis (https://www.isth.org), from the American Society of Hematology (https://www.hematology.org/ covid-19) and from the Society for Thrombosis and Haemostasis Research (http://gth-online.org), the Working Party on Hemostasis (Swiss Society of Hematology) proposes the following recommendations for pharmacological thromboprophylaxis in COVID-19 patients in the acute setting. Suggestions will be regularly updated:

- All in-hospital COVID-19 patients should receive pharmacological thromboprophylaxis according to a risk stratification score, unless contraindicated.
- In patients with creatinine clearance >30 ml/min, low molecular weight heparin (LMWH) should be administered according to the prescribing information. An increased dose should be considered in overweight patients (>100 kg).
- In patients with creatinine clearance <30 ml/min, unfractionated heparin (UFH) subcutaneously twice or three times daily or intravenously should be administered according to the prescribing information. An increased dose should be considered in overweight patients (>100 kg).
- Anti-Xa activity should be monitored when indicated (e.g., evidence of renal dysfunction).
- Antithrombin need not be monitored but this could be considered on an individual basis in cases of disseminated intravascular coagulation or sepsis-induced coagulopathy or heparin resistance.
- We suggest regularly monitoring prothrombin time, D-dimers, fibrinogen, the platelet count, lactate dehydrogenase (LDH), creatinine and alanine aminotransferase (ALT) (daily or at least 2–3 times per week).
- In patients in intensive care with a large increase in D-dimers, severe inflammation, or signs of hepatic or renal dysfunction or imminent respiratory failure, intermediate or therapeutic dosing of LMWH or UFH should be considered, according to the bleeding risk.
- Heparin-induced thrombocytopenia (HIT) should be considered in patients with fluctuations in platelet counts or signs of heparin resistance.
- In patients undergoing extracorporeal membrane oxygenation (ECMO) treatment we suggest maintaining UFH at doses bringing anti-Xa activity into the therapeutic range.
- There are no data on the use of direct oral anticoagulants.

\textbf{Disclosure statement}

No financial support and no other potential conflict of interest relevant to this article was reported.
References


